Skip to content

A feasibility study on accelerated radiotherapy in cancers of throat and voice box

A Pilot study on moderate accelerated radiotherapy in locoregionally advanced squamous cell carcinomas of Hypopharynx and Larynx - a prospective feasibility study - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/03/082659
Enrollment
40
Registered
2025-03-18
Start date
Unknown
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C139- Malignant neoplasm of hypopharynx,unspecified Health Condition 2: C329- Malignant neoplasm of larynx, unspecified

Interventions

Intervention1: radiation treatment: extra fraction of radiation per week, i.e patient receives 6 days a week radiotherapy , one extra dose on saturday every week instead of regular 5 days a week treat

Sponsors

Cancer Institute Adyar WIA
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.All patients of newly diagnosed locally advanced stage III-IV squamous cell carcinomas of hypopharynx and larynx subsite, not for surgery, eligible to receive Radical radiotherapy with or without chemotherapy. 2.Age between 18 to 75 years

Exclusion criteria

Exclusion criteria: 1.Patients with distant metastatic disease 2.Those who have undergone surgery and recurrent disease status. Patient is mentally incapacitated or has a significant emotional aspect

Design outcomes

Primary

MeasureTime frame
The primary end point would be treatment completion rates (proportion of patients completing the planned treatment) for feasibility 2.The proportion of patients who develop Grade 3 and 4 toxicity as per RTOG/CTCAE criteria.Timepoint: The treatment completion rates (proportion of patients completing the planned treatment) will be assessed at the end of radiotherapy treatment 2.The proportion of patients who develop Grade 3 and 4 toxicity as per RTOG/CTCAE criteria will be assessed every week during radiotherapy, 6 weeks post therapy and then monthly once upto 1 year

Secondary

MeasureTime frame
The proportion of patients developing complete response, partial response and progressive disease during follow up. Timepoint: 2 years

Countries

India

Contacts

Public ContactSowmiya Sampathrajan

Cancer Institute, Adyar, WIA

doctorsowmiyapgi@gmail.com7042811034

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026